Conference Coverage

AAGP: Treating Parkinson’s psychosis takes balance on risk/benefit tightrope


 

EXPERT ANALYSIS FROM THE AAGP ANNUAL MEETING

References

The drug also is being investigated for Alzheimer’s disease psychosis.

Dr. Marsh disclosed that she had received honoraria from Roche Pharmaceuticals in 2013, and has received royalties from Taylor & Francis/Informa.

msullivan@frontlinemedcom.com

On Twitter @alz_gal

Pages

Recommended Reading

Pimavanserin reduced Parkinson’s psychosis without motor worsening
MDedge Psychiatry
Meta-analysis confirms pramipexole calms restless legs
MDedge Psychiatry
Number of restless leg movements during sleep may predict AFib progression
MDedge Psychiatry
Online stem cell clinics lack adequate regulation, researchers charge
MDedge Psychiatry
Pseudobulbar affect: More common than you’d think
MDedge Psychiatry
Old standby valproic acid appears effective against hyperactive delirium
MDedge Psychiatry
Dopamine receptor agonists trigger impulse control disorders
MDedge Psychiatry
Extended-release carbidopa-levodopa approved for Parkinson’s
MDedge Psychiatry
Intestinal carbidopa-levodopa gets FDA approval
MDedge Psychiatry
Pathologic proteins in Alzheimer’s, Parkinson’s also collect in skin cells
MDedge Psychiatry